JP2025172140A5 - - Google Patents

Info

Publication number
JP2025172140A5
JP2025172140A5 JP2025145434A JP2025145434A JP2025172140A5 JP 2025172140 A5 JP2025172140 A5 JP 2025172140A5 JP 2025145434 A JP2025145434 A JP 2025145434A JP 2025145434 A JP2025145434 A JP 2025145434A JP 2025172140 A5 JP2025172140 A5 JP 2025172140A5
Authority
JP
Japan
Prior art keywords
amino acid
composition according
peptide
terminus
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025145434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025172140A (ja
Filing date
Publication date
Priority claimed from JP2021521472A external-priority patent/JP7426121B2/ja
Application filed filed Critical
Publication of JP2025172140A publication Critical patent/JP2025172140A/ja
Publication of JP2025172140A5 publication Critical patent/JP2025172140A5/ja
Pending legal-status Critical Current

Links

JP2025145434A 2018-10-22 2025-09-02 Cxcr3の切断可能な活性化因子および使用方法 Pending JP2025172140A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862748711P 2018-10-22 2018-10-22
US62/748,711 2018-10-22
JP2021521472A JP7426121B2 (ja) 2018-10-22 2019-10-18 Cxcr3の切断可能な活性化因子および使用方法
PCT/US2019/056955 WO2020086400A1 (en) 2018-10-22 2019-10-18 Cleavable activators of cxcr3 and methods of use
JP2023198254A JP7798368B2 (ja) 2018-10-22 2023-11-22 Cxcr3の切断可能な活性化因子および使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023198254A Division JP7798368B2 (ja) 2018-10-22 2023-11-22 Cxcr3の切断可能な活性化因子および使用方法

Publications (2)

Publication Number Publication Date
JP2025172140A JP2025172140A (ja) 2025-11-20
JP2025172140A5 true JP2025172140A5 (cg-RX-API-DMAC7.html) 2026-03-30

Family

ID=70330587

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021521472A Active JP7426121B2 (ja) 2018-10-22 2019-10-18 Cxcr3の切断可能な活性化因子および使用方法
JP2023198254A Active JP7798368B2 (ja) 2018-10-22 2023-11-22 Cxcr3の切断可能な活性化因子および使用方法
JP2025145434A Pending JP2025172140A (ja) 2018-10-22 2025-09-02 Cxcr3の切断可能な活性化因子および使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021521472A Active JP7426121B2 (ja) 2018-10-22 2019-10-18 Cxcr3の切断可能な活性化因子および使用方法
JP2023198254A Active JP7798368B2 (ja) 2018-10-22 2023-11-22 Cxcr3の切断可能な活性化因子および使用方法

Country Status (12)

Country Link
US (2) US12110316B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870212A4 (cg-RX-API-DMAC7.html)
JP (3) JP7426121B2 (cg-RX-API-DMAC7.html)
KR (2) KR102984527B1 (cg-RX-API-DMAC7.html)
CN (2) CN113038965B (cg-RX-API-DMAC7.html)
AU (2) AU2019365654B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007414A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116325A1 (cg-RX-API-DMAC7.html)
IL (2) IL282431B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004496A (cg-RX-API-DMAC7.html)
SG (1) SG11202103497WA (cg-RX-API-DMAC7.html)
WO (1) WO2020086400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103497WA (en) * 2018-10-22 2021-05-28 Univ Pittsburgh Commonwealth Sys Higher Education Cleavable activators of cxcr3 and methods of use
GB202208950D0 (en) * 2022-06-17 2022-08-10 Ucl Business Ltd Treatment of the corneal endothelium
US20260201006A1 (en) * 2022-11-30 2026-07-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Coacervate formulations of cxcr-activating peptides for controlled release in ophthalmic and topical treatments

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994292A (en) 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20070116669A1 (en) 2002-09-13 2007-05-24 Chemokine Therapeutics Corporation Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
GB2377444A (en) 2001-04-09 2003-01-15 Smithkline Beecham Plc Chemokine-family polypeptide
CA2525647A1 (en) * 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
WO2013032853A1 (en) 2011-08-26 2013-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activators of cxcr3 for the treatment of angiopathies of the eye
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
WO2015021058A2 (en) * 2013-08-05 2015-02-12 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
EP3096777B1 (en) * 2014-01-21 2021-01-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Goblet cell replacement therapy
EA035259B1 (ru) * 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
EP3478321A4 (en) * 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
AU2017364818C1 (en) * 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
SG11202103497WA (en) 2018-10-22 2021-05-28 Univ Pittsburgh Commonwealth Sys Higher Education Cleavable activators of cxcr3 and methods of use

Similar Documents

Publication Publication Date Title
US7083983B2 (en) Inhibitors of the interaction between P53 and MDM2
CA1339623C (en) Lhrh antagonists
US20050090448A1 (en) Peptides that inhibit complement activation
CN101265299A (zh) 来自杀菌性通透性增强蛋白的功能区的生物活性肽及其应用
US9777051B2 (en) TFPI inhibitors and methods of use
CN105451755A (zh) 铁调素类似物和其用途
JPH09507501A (ja) 殺菌性/透過性が向上したタンパク質の機能領域に由来する生物学的に活性なペプチドおよびその使用
RU2007110981A (ru) Урокортин iii и его использование
JP2011518179A5 (cg-RX-API-DMAC7.html)
EP3131925B1 (en) Modified relaxin b chain peptides
CN101273059A (zh) 治疗活性的α-MSH类似物
JP2023116739A5 (cg-RX-API-DMAC7.html)
JP2022512770A5 (cg-RX-API-DMAC7.html)
US7244701B2 (en) Diuretic peptide conjugate
WO2022125606A2 (en) Peptide therapeutics for treating alzheimer's disease and related conditions
KR20250042844A (ko) 결장 세정을 위한 조성물 및 위장 장애의 치료
JP4812347B2 (ja) 抗菌性ペプチド
CN101808655B (zh) 衍生自纤溶酶原激活物抑制剂-1的肽和其应用
Zikos et al. Comparative evaluation of four trityl‐type amidomethyl polystyrene resins in Fmoc solid phase peptide synthesis
CN100413883C (zh) 选择性地与p-选择蛋白结合的肽化合物
JP2009509552A (ja) 先天免疫を調節することによる感染の処置および予防を含む、免疫関連疾患障害の処置および予防のための新規ペプチド
US6964948B2 (en) Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
Sakura et al. Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity
WO2005119266A1 (en) Sr-a antagonists
EP1337551B1 (en) Substance p analogs for the treatment of cancer